Sfoglia per AUTORE
ROGNONI C
Collezione ASL Asti

  

Items : 5

The expert in haemostasis and thrombosis: Is an economic analysis feasible? in Value in Health

2017
ASL Asti

Rognoni C; Liberato L; Marchetti M; Testa S; Quaglini S;

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis in Journal of Thrombosis and Thrombolysis

2014
ASL Asti

Rognoni C; Marchetti M; Quaglini S; Liberato NL;

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: A cost-effectiveness analysis in Clinical Drug Investigation

2014
ASL Asti

Rognoni C; Marchetti M; Quaglini S; Liberato NL;

Cost-effectiveness of edoxaban, apixaban, rivaroxaban and dabigatran versus warfarin for stroke prevention in nonvalvular atrial fibrillation in Haematologica

2014
ASL Asti

Marchetti M; Liberato NL; Rognoni C; Quaglini S;

Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: A cost-utility analysis in Annals of Oncology

2012
ASL Asti

Liberato NL; Rognoni C; Rubrichi S; Quaglini S; Marchetti M; Gorlia T; Licitra L; Vermorken JB;